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ABSTRACT 
The cefotaxime is a broad spectrum cephalosporin antibiotic. It is mainly used in the treatment of bacterial infections. Cefotaxime is 
a suitable candidate for controlled release administration due to its short elimination time 1 hour. The main aim of the present 
investigation is to increase the gastric residence time by preparing floating drug delivery by using raft forming approach thereby 
improving bioavailability. The prepared Cefotaxime floating drug delivery by using raft forming approach were evaluated for 
hardness, weight variation, thickness, friability, drug content uniformity, total floating time, In-vitro dissolution studies and 
buoyancy lag time. Floating tablets were formulated using direct compression technique. Various polymers are used in the 
formulation they Micro crystalline cellulose used as binder, HPMC K15M, Guargum used as hydrophilic polymers, Chitosan, 
Sodium bicarbonate was incorporated as an effervescent substance, Sodium alginate used as viscous gel forming agent, Magnesium 
streate used as lubrication, talc was used as diluent. The formulated Cefotaxime tablet to be evaluated the following parameters as 
follow Weight variation (mg), Hardness, Thickness, Friability, Drug content uniformity, Floating lag time, the in vitro cumulative 
amount of drug released was shown the F7 is 99.28% within 45 minutes the comparative studies with marketed formulations F7 
show the better results.  
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INTRODUCTION 
The Oral administration is the most convenient and 
preferred means of any drug delivery to the systematic 
circulation 
1
. Oral controlled release drug delivery have 
recently been of increasing interest in pharmaceutical 
field to achieve improved therapeutic advantages, such 
as ease of dosing administration, patient compliance and 
flexibility in formulation. This route has high patient 
acceptability, primarily due to ease of administration. 
Over the years, oral dosage forms have become 
increasingly sophisticated with major role being played 
by control release drug delivery system 
2
. The Control 
release drug delivery system release drug at a 
predetermined rate, as determined by drug’s 
pharmacokinetics and desired therapeutic concentration. 
Raft forming system has received much attention for the 
delivery of antacids and drug delivery for 
gastrointestinal infections and disorders. The basic 
mechanism involved in the raft formation includes the 
formation of viscous cohesive gel in contact with gastric 
fluids, wherein each portion of the liquid swells forming 
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a continuous layer called raft. The raft floats because of 
the buoyancy created by the formation of co2 and act as 
barrier to prevent the reflux of gastric content like HCl 
and enzymes into the esophagus. Usually, the system 
contains a gel forming agent and alkaline bicarbonates 
or carbonates responsible for the formation of to make 
the system less dense and float on the gastric fluids 
3
. 
The floating drug delivery system by raft forming 
method enhances the absorption of drug in stomach and 
also to increase the bioavailability of drug. Gastric 
retentive time is increased because of buoyancy studies 
to avoidance of gastric irritation 
4
. These delivery system 
also used to reduce the development of drug resistant 
bacteria and maintain the effectiveness of cefotaxime 
and other antibacterial drugs. It should be used only to 
treat or prevent infections that are proven or strongly 
suspected to be caused by bacteria. Cefotaxime sodium 
is a bactericidal agent that acts by inhibition of bacterial 
cell wall synthesis 
5
. Cefotaxime has activity in the 
presence of some beta lactamases, both penicillinases 
and cephalosporinases, of Gram negative and Gram 
positive bacteria. Cefotaxime is a β-lactam antibiotic as 
a class, β-lactams inhibit bacterial cell wall synthesis by 
binding to one or more of the penicillin-binding proteins. 
MATERIALS AND METHODS:  
Cefotaxime was procured as a gift sample from Hetero 
Drug Limited, Hyderabad, India. Microcrystalline 
cellulose, Sodium alginate & HPMCK15M was obtained 
from Pharmaceutical Pvt Ltd, Mumbai. Guar gum & 
chistosan was obtained from India sea foods cochin, 
Sodium bicarbonate, talc & Magnesium stearate was 
obtained form S.D. Fine Chemical Ltd, Mumbai. All 
other reagents used were of analytical grade.  
Methodology 
Compatability Studies 
FTIR Studies: The compatibility between pure drug and 
polymer like Cefotaxime, HPMC K15M, guar gum, 
chitosan and mixture of compounds were prepared in the 
form of KBr Pellets and subjected for scanning from 
4000 cm‾1 to 400 cm‾1 using FTIR spectroscopy 6. 
Formulation of Floating Tablet of Cefotaxime    
The Floating Raft forming approach tablets of 
cefotaxime were prepared through direct compression 
method. The preparations of Cefotaxime by various 
steps involved in tablet production are sieving, mixing, 
lubrication and compression 
7
. Microcrystalline cellulose 
use as binder, HPMC K 15M used as synthetic 
hydrophilic polymer. Guar gum and chitosan used as 
natural hydrophilic polymer. Sodium alginate use as 
viscous gel forming, sodium bicarbonate used as gas 
generating agent. Talc is used as diluents, magnesium 
stearate used as lubricant. Finally, the powder mixture 
was compressed into tablets using rotator tablet 
punching machine at the weight of 500mg each.  The 
below expressed gastro retentive drug delivery of 
cefotaxime tablets performed a different formulation 
from F1 to F9 batches study with various concentrations 
of different polymers. 
 
Table 1: Formulation of gastro retentive of cefotaxime tablet prepared by using different polymers 
 
Ingrdients 
Formulation code 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Cefotaxime (mg)    150 150 150 150 150 150 150 150 150 
Micro crystalline cellulose (mg) 165 115 85 165 115 85 165 115 85 
Sodium alginate (mg) 70 70 90 70 70 90 70 70 90 
HPMC K15M (mg) 60 110 110 --- --- --- --- --- --- 
Guar gum (mg) --- --- --- 60 110 110 --- --- --- 
Chitosan (mg) --- --- --- --- --- --- 60 110 110 
Sodium Bicarbonate (mg) 40 40 50 40 40 50 40 40 50 
Talc (mg) 9 9 9 9 9 9 9 9 9 
Magnesium stearate (mg) 6 6 6 6 6 6 6 6 6 
Total (mg) 500 500 500 500 500 500 500 500 500 
All formulation are shown in mg 
Pre Compression Parameters 
Angle of repose: Angle of repose is defined as the 
maximum angle between the surface of pile of the 
powder and the horizontal plane 
10
. Fixed funnel method 
was used. A funnel was fixed with its tip at a given 
height (h), above a flat horizontal surface on which a 
graph paper was placed. Powder was carefully poured 
through the funnel until the apex of the conical pile 
formed just reached the tip of the funnel 
8
. These studies 
were carried out before and after incorporating 
lubricant/glidant. The angle of repose (ѳ) was then 
calculated.      
            Ѳ = tan‾1 (h/r) 
           Where ѳ = Angle of repose, 
                       h =Height of pile, 
                       r = Radius of the base of pile. 
Bulk density: Bulk density was determined by using 
bulk density apparatus, during measurement accurately 
weighed quantity of the powder were taken in a 
measuring cylinder and recording the volume and weight 
of the total powder 
9
. Bulk density is expressed in gm/ml 
and is given by, 
  BD=W/Vo 
Where, BD = Bulk density (gm/ml) 
W = weight of powder (gm) 
Vo = Initial volume of the powder (ml) 
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Tapped density: Tapped density was determined by 
using Tapped density apparatus during measurement 
accurately weighed quantity of the powder were taken in 
a measuring cylinder and recording the volume of 
powder after 30 tapping and weight of the total powder 
10
. 
  TD =W/VF 
Where, TD= Tapped density (gm/ml) 
W = weight of powder (gm) 
VF = Final volume of powder (ml) 
 
Compressibility index (or) Carr’s index: 
Compressibility index is an important measure that can 
be obtained from the bulk and tap densities 
11
. A 
material having values less than 20 to 30% is defined as 
the free flowing material, based on the apparent bulk 
density and tapped density, the percentage 
compressibility of the bulk drug was determined by 
using the following formula. 
Compressibility index = 
     
  
× 100 
Where, TD = Tapped density of the powder, 
             BD = Bulk density of the powder. 
Hausner’s ratio: It indicates the flow properties of the 
powder.  The ratio of tapped density to bulk density of 
the powder is called Hausner’s ratio.  
              Hausner’s Ratio=TD/BD 
Where, TD = Tapped density of the powder, 
             BD = Bulk density of the powder. 
Post Compression Parameters 
Hardness: The hardness of ten tablets was measured 
using Monsanto tester. Resistance of the tablet during 
transportation or breakage under storage conditions and 
handling before usage depends on its hardness 
12
. The 
hardness was measured in terms of kg/cm
2
. Five tablets 
were chosen randomly and tested for hardness. The 
average hardness of five tablets was recorded.  
Thickness: Thickness was measured using a calibrated 
vernier calliper. It was determined for check the 
thickness of tablet 
13
. Five tablets of each formulation 
were picked randomly and thickness was measured 
individually. 
Friability: The friability of the prepared tablets was 
determined using Roche friability apparatus. It is 
expressed in percentage (%). To calculate the percentage 
friability determines 10 tablets initial weight and 
transferred into friabilator. The friabilator was operated 
at 25 rpm for four minutes 
14
. After four minutes the 
tablets were weighed again. Then % friability was then 
calculated using formula.  
  % Friability =
                 
         
×100 
Weight variation: The weight of the tablet being made 
was determined to ensure that a tablet contains the 
proper amount of drug. Twenty tablets were selected at 
random from each formulation and weighed on 
electronic weighing balance. The average weight of the 
tablets was determined 
15
. The weight of individual 
tablets was compared with the average weight variation.  
Drug content uniformity: The drug content of prepared 
tablets was accurately weight and finely powered by 
pestle in a mortar. Weighed tablet of each powder 
equivalent to 400mg of cefotaxime was transferred in to 
volumetric flask, dissolved in 60ml of 0.1N HCL and 
content of the flask were sonicated for 15 minutes. Then 
the volume was made up to100ml 
16
. The samples were 
analyzed UV-Visible spectrophotometer, and 
concentration of the drug in the sample was calculated.  
In-Vitro Buoyancy Studies: The in vitro buoyancy was 
determined by floating lag time. The time between 
introduce of dosage form and its buoyancy on the 
simulated gastric fluid and the time during which the 
dosage form remain buoyant were measured. The time 
taken for dosage form to emerge on surface of medium 
called floating lag time. Method described by the tablets 
was placed in a 100ml beaker containing 0.1 N HCL. 
The time required for the tablet to rise to the surface and 
float was determined as floating lag time 
17
. 
In-vitro dissolution studies: Dissolution of the tablets 
was carried out on USP XXXIII dissolution type II 
apparatus using paddle. The tablet was fixed to the 
paddle by hydration mechanism 900 ml of 0.1N HCL as 
dissolution medium was filled in a dissolution vessel and 
the temperature of the medium was set at 37± 0.5
o
c. The 
rotational speed of the paddle was set at 100 rpm 
18
. At 
particular intervals 5 ml of sample was withdrawn at 
predetermined time intervals of 5 mints, 10 mints, 15 
mints, 20 mints, 25 mints, 30 mints, 35 mints, 40 mints, 
45 mints and same volume of fresh medium was 
replaced. The withdrawn samples were diluted to 10 ml 
with 0.1N HCL, filtered and analyzed on UV 
spectrophotometer at 752 nm 0.1NHCL using buffer as a 
blank. Percentage cumulative drug release was 
calculated.  
Raft strength measurement by in house method: A 
tablet powder equivalent to unit dose was transferred to 
150 ml of 0.1N HCL and maintained at 37ºc in a 250 ml 
glass beaker. Each raft was allowed to form around an 
L- shaped wire probe (diameter: 1.2mm) held upright in 
the beaker throughout the whole period (30 min) of raft 
development. Raft strength was estimated using the 
modified balance method 
19
. Water was added drop wise 
to the pan and the weight of water required to break the 
raft was recorded.  
Data analysis: To analyze the mechanism of release and 
release rate Zero order, first order, Higuchi matrix and 
Peppa’s model. Based on the r-value, the best-fit model 
was selected  
Zero order kinetics: Drug dissolution from 
pharmaceutical dosage forms that do not disaggregate 
and release the drug slowly, assuming that the area does 
not change and no equilibrium conditions are obtained 
can be represented by the following equation 
20
. 
             Qt = Q o + K o t 
Where Qt = amount of drug dissolved in time t, 
            Q o = initial amount of the drug in the solution, 
            K o = zero order release constant. 
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First order kinetics: To study the first order release rate 
kinetics, the release rate data were fitted to the following 
equation 
21
.        
           Log Qt = Log Q o K1 t/2.303 
Where Qt is the amount of drug released in time t, Q o is 
the initial amount of drug in the solution and K1 is the 
first order release constant. 
Higuchi’s model: Higuchi’s developed several 
theoretical models to study the release of water soluble 
and low soluble drugs incorporated in semisolids and/or 
solid matrices 
22
. Mathematical expressions were 
obtained for drug particles dispersed in a uniform matrix 
having as diffusion media. And the equation is,  
          Mt/M∞ = KH t1/2  
Where,  
Mt and M∞ are cumulative amount of drug release at 
time t and infinite time,  
KH = Higuchi dissolution constant reflection 
formulation characteristics.  
If the Higuchi model of drug release is obeyed, then a 
plot of Mt/M∞ versus t1/2 will be straight line with 
slope of KH.  
Korsmeyer- Peppas Model: The power law describes 
the fractional drug release is exponentially related to the 
release time and adequately describes the release of drug 
from slabs, cylinders and spheres, as expressed in 
following equatiion 
23
. 
                 Mt / M∞ = Ktn  
                 Log (Mt / M∞) = log K + n log t  
Stability Studies: Accelerated stability study of gastro 
retentive drug delivery of cefotaxime (100mg) brand 
name was claforan by using raft forming approach. 
Stability study of tablets containing Cefotaxime was 
performed at following temperatures for one month and 
three months 
24
. 
Long term testing: 25oC/ 60%RH (1Month) (3Month) 
Accelerated testing: 40oC/75% RH (1Month) (3Month) 
 
RESULTS AND DISCUSSION 
Preformulation studies: 
 
Figure 1:  FTIR Spectrum of Cefotaxime 
Drug and interaction (FTIR) study: From the spectra 
of Cefotaxime, excipients physical mixture of drug was 
observed that all characteristic peaks of Cefotaxime 
were present in the combination spectrum, thus 
indicating compatibility of the Cefotaxime and 
excipients. IR spectra of individual polymers and 
combination of Cefotaxime with all individual polymers. 
As shown in table 2 & figure 1-6. 
 
 
Figure 2: FTIR Spectrum of HPMC K15M 
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Figure 3:  FTIR Spectrum of Guargum 
 
 
Figure 4: FTIR Spectrum of Chitosan 
 
 
Figure 5:  FTIR Spectrum of Microcrystalline cellulose 
 
 
Figure 6:  FTIR Spectrum of Mixtrue of compounds 
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Table 2: Interpretation of Drug, Polymers with mixture of compounds 
SI.No Name of the sample Observed Peak Bond Functional Group 
1 Sample 1 (Pure drug 
(Cefotaxime) 
  
666 (s)= C-H bend Alkenes  
1017 (s)C-O stretch Alcohol, carboxylic acid 
1244 (s) C-N stretch Aromatic amines 
3204 (s, b) O-H stretch H-bonded alcohols, phenols 
2 Sample 2 
(HPMCK15M ) 
 
753 (m) C-Cl stretch alkyl halides 
1669 (s) C=O stretch Carbonyl 
2932 (m) O-H stretch Carboxylic acids 
3194 (m) =C-H stretch Alkenes 
3 Sample 3 (Guargum) 
 
749 (m) C-Cl stretch  Alkyl halides 
1322 (m) N-O symmetric 
stretch  
Nitro compounds 
1602 (m) N-H bend      1
0 
amines 
3055 (m) O-H stretch Carboxylic acid 
4 Sample 4 (Chitosan) 
 
745 (s)= C-H bend Alkenes 
1056  (s)C-O stretch Alcohol, carboxylicacid,       
esters, ethers 
1331 (s)C-N stretch Aromatic amines 
5 
 
Sample 5 
(Microcrystalline 
cellulose) 
754 (m) C-Cl stretch alkyl halides 
1140 (m) C-N stretch Aliphatic amines 
2996 (m) C-H stretch Alkanes  
6 
 
Sample 5 
(Microcrystalline 
cellulose) 
 
 
564 (m) C-Br stretch Alkyl hadlides 
749 (s) =C-H bend Alkenes 
1133 (m) C-N stretch Aliphatic amines 
2145 (w) –C # C- stretch Alkynes 
3053 (m) =C-H stretch Alkenes 
 
Pre-compression parameters: 
Angle of repose: The results obtained for angle of 
repose for all the formulations. The values were found to 
be in the range of 21°.32' to 30°.39'. Results as shown in 
table 3. All the formulation showed the angle of repose 
below 30°, which indicates good flow. 
Bulk density & Tapped density: The loose bulk 
density and tapped bulk density for all the formulations 
varied from 0.38 gm/cm
3
 to 0.43 gm/cm
3
 and 
0.41gm/cm
3
 to 0.50 gm/cm
3
 respectively. The values 
obtained lies within the acceptable range and no large 
difference found between loose bulk density and tapped 
density. These results help in calculating the % 
compressibility of the powder as shown in table 3. 
Percentage compressibility (carr’s consolidation 
index): The percentage compressibility of powder mix 
was determined by the equation given for carr’s 
consolidation index. The percentage compressibility lies 
within the range of 7.41 to 14.15 which indicates that the 
flow of the tablet mixture of various formulations is 
good to excellent. Results as shown in table 3. 
Hausner’s ratio: The Hausner’s ratio of powder mix 
was determined by the data of loose bulk density and 
tapped bulk density. The Hausner’s ratio for all the 
formulations lies within the range of 1.05 to 1.20, which 
indicates flow of powder is excellent.  
 
Table 3: Evaluation of pre-compression parameters of Cefotaxime with different formulations 
Formulation 
Code 
Bulk 
density(g/cc) 
MEAN±SD 
Tapped 
density(g/cc) 
MEAN±SD 
Hausner’s 
ratio 
MEAN±SD 
Compressibility 
index (%) 
MEAN±SD 
 Angle of 
repose (θ) 
MEAN±SD 
   F1   0.40±0.03   0.44±0.05   1.06±0.02 7.50±0.04 27.55±0.04 
   F2   0.42±0.05   0.50±0.04   1.29±0.03 14.15±0.02 30.39±0.03 
   F3   0.43±0.03   0.41±0.02   1.16±0.05 10.52±0.05 23.31±0.02 
   F4   0.41±0.04   0.42±0.05   1.14±0.06 10.25±0.04 24.81±0.05 
   F5   0.41±0.02   0.43±0.02   1.05±0.02 7.69±0.02 28.65±0.02 
   F6   0.42±0.06   0.45±0.07   1.16±0.04 10.25±0.05 27.74±0.03 
   F7   0.40±0.05   0.46±0.05   1.09±0.02 7.50±0.07 28.39±0.02 
   F8   0.38±0.03   0.43±0.02   1.07±0.03 7.41±0.02 23.81±0.06 
   F9   0.41±0.04   0.45±0.06   1.10±0.06 7.69±0.06 24.81±0.05 
Each value represents the mean ± standard deviation (n=3) 
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Post compression parameters: 
Shape and thickness: Macroscopic examination of the 
tablets from each formulation showed circular shape 
with no cracks. Results as shown in table 4. The 
thickness of tablet randomly was measured using vernier 
callipers. 
Weight variation test: All the formulations passed 
weight variation test as the percent weight variation was 
within the pharmacopoeia limits of ±5%. It was found to 
be from 399.41 to 499.09 mg. Results as shown in table 
4. None of the formulations were exceeding the limit 
±5% specified by IP. Thus all the formulations were 
found to comply with the IP standard. 
Hardness of the tablets: The tablet hardness of all the 
formulations was checked using Monsanto hardness 
tester, by the method described in methodology section. 
The average hardness of all the batches is in the range of 
4.5 to 3.5 kg/m
2
. The lower standard deviation values 
indicated that the hardness of all the formulations were 
almost uniform in specific method and possess good 
mechanical strength with sufficient hardness. Results as 
shown in table 4.  The hardness of all formulations was 
found to be in acceptable range. 
Friability of the tablets: The friability test is designed 
to evaluate the ability of the tablet to withstand abrasion 
in packaging, handling and shipping. A number of tables 
were weighed and placed in tumbling apparatus where 
they were exposed to rolling and 50 resolutions resulting 
from freefalls within the roche’s apparatus. Results as 
shown in table 4. The percentage friability for all the 
formulations lies in the range of 0.12% to 0.45%, which 
was found to be in limit (i.e. <1%). 
Estimation of drug content: All the formulations were 
evaluated for the drug content estimation in 0.1NHCl 
sample of tablets using the procedure described in 
methodology section. Results as shown in table 4. The 
drug content values for all the formulations are in the 
range of 98 to 99%. 
 
Table 4: Evaluation of Post Compression Parameters of Different Formulations cefotaxime tablet floating drug 
delivery by using raft forming approach 
Formulation 
code 
Hardness 
(kg/cm
2
 ) 
MEAN±SD 
(n=3) 
Thickness 
(mm) 
MEAN±SD 
(n=3) 
Weight 
variation(mg) 
MEAN±SD  
(n=20) 
Friability 
(%) 
MEAN±SD 
(n=3) 
Drug content 
(%) 
(n=2) 
    F1     3.9±0.3   6.0±0.4   399.41±0.32    0.20±0.17 98.23 
    F2     4.3±0.1   6.1±0.1   460.09±0.57    0.12±0.15 99.52 
    F3     4.1±0.3   5.8±0.2   450.57±0.26    0.35±0.14 98.48 
    F4     4.4±0.4   6.4±0.3   443.46±0.39    0.29±0.12 99.01 
    F5     3.9±0.2   6.7±0.2   467.33±0.23    0.30±0.16 98.26 
    F6     4.0±0.3   6.5±0.1   478.25±0.62    0.35±0.14 99.11 
    F7     4.2±0.2   6.8±0.3   434.72±0.47    0.42±0.13 99.10 
    F8     4.4±0.2   6.9±0.3   499.01±0.28    0.45±0.18 98.65 
    F9     3.9±0.3   6.3±0.2   423.03±0.43    0.43±0.16 98.47 
Each value represents the mean ± standard deviation 
 
In-vitro drug release studies: The In-vitro dissolution 
study of Cefotaxime tablet floating drug delivery by 
using raft forming approach, 0.1N HCl as dissolution 
medium. The In-vitro drug release study of Cefotaxime 
tablets from each batch (F1 to F9) was carried out by 
using 0.1N HCl for 45 Mints. The samples were 
withdrawn at specified time intervals and analyzed by 
UV-visible spectrophotometer. Percentage drug release 
was calculated on the basis of mean amount gastro 
retentive of Cefotaxime present in respective 
formulation. The cumulative percentage of drug release 
of floating drug delivery of Cefotaxime on y-axis was 
plotted against time on x-axis to obtain drug release 
profiles. 
Drug Release Kinetics: The release constant was 
calculated from the slope of the appropriate plots, and 
the regression coefficient (r
2
) was determined   The drug 
release data obtained were extrapolated by Zero order, 
First order,  Higuchi  model  and  Korsmeyer-Peppas 
plot  for  Best  Formulation  F7. The   release kinetics   
shows   that   the   release   of   drug followed zero order 
release in all the formulations. 
 
Figure 7:  In Vitro dissolution Studies cefotaxime 
tablet floating drug delivery by using raft forming 
approach
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Table 5:  Release kinetics of cefotaxime tablet floating drug delivery by using raft forming approach F1 to F5 
 
Table 6: Release kinetics of cefotaxime tablet floating drug delivery by using raft forming approach F6 to F9 
             
In-vitro Buoyancy Studies: The all formulation were showed good floating lag time and total floating time. The FLT 
and TFT of the tablets mainly depend on the type of polymer and their concentrate, as shown in figure 8 & table 7. 
 
 
Figure 8: Buoyancy floating of formulated floating tablets 
                           
Table 7: Floating lag time of the gastro retentive tablets (F1-F9) 
Formulation Code Floating lag time (sec) Total floating time (hour) 
F1 23 12 
F2 36 12 
F3 28 12 
F4 42 12 
F5 10 10 
F6 16 10 
F7 18 12 
F8 26 12 
F9 31 12 
 
Stability Study: Optimized formulation F7 was subjected to stability studies for 1 to 3 months and the tablets were 
tested for drug content and dissolution. The results obtained were as in the following figure 9.  
Model Equation F1 F2 F3 F   4 F   5 
R
2
 m R
2
 m R
2
 M R
2
 m R
2
 M 
Zero order Mo-Mt=kt 0.655 69.4 0.939 1123 0.007 15.93 0.202 72.88 0.928 1414 
First order  InM=InMo 0.494 0.061 0.540 0.067 0.257 0.038 0.352 0.044 0.438 0.062 
Higuchi’s 
Matrix 
M0−Mt = 
kt1/2 
0.516 4508 0.767 7420 0.023 212.0 0.189 515.5 0.803 9618 
Korsmeyer-
Peppar 
log (M0-Mt)= 
log k + n logt 
0.835 2.354 0.884 2.545 0.572 1.709 0.663 1.813 0.806 2.517 
Model Equation F6 F7 F8 F9 
R
2
 m R
2
 m R
2
 M R
2
 M 
Zero order Mo-Mt=kt 0.917 15.49 0.949 154.4 0.937 1593 0.945 139.7 
First order  InM=InMo 0.481 0.052 0.465 0.051 0.399 0.061 0.478 0.051 
Higuchi’s 
Matrix 
M0−Mt = kt1/2 0.798 1057 0.848 1067 0.899 1149 0.836 960.9 
Korsmeyer-
Peppar 
log (M0- 
Mt)= log k + n logt 
0.835 2.032 0.827 2.033 0.785 2.560 0.838 2.018 
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Figure 9: Stability studies of Optimized In-vitro 
Cumulative % Drug release of F7 
Comparison of dissolution profile of optimized 
formulation (F7) with marketed product: The 
prepared all F7 formulations, the tablets made with 
combination of chitosan F7 showed better results of 
dissolution. It has showed 98.6% dissolution in 12 
hours. This formulation was compared with marketed 
formulation shown in figure 10. 
 
Figure 10:   Comparison of dissolution profile of F7 
and Marketed product 
SUMMARY 
The cefotaxime drug is used for the treatment for 
antibacterial disease by the mechanism bactericidal 
action of cefotaxime inhibits cell wall synthesis. It binds 
the penicillin binding proteins. The main of this project 
work to improve the patient complains quick relies of 
the drug, improve bioavailability and improve 
therapeutic effectiveness. For this purpose formulate the 
floating drug delivery of cefotaxime tablet by using raft 
forming approach. Drug polymer compatibility studies 
by observing physical observation, FTIR, analysis 
revealed that there was no significant physical & 
chemical interaction between the drug and polymers. 
Hence, the selected raw materials were more suitable for 
the formulation of cefotaxime tablet linearity of the 
curve was observed in the calibration curve, which was 
found to be wavelength 752 nm. Nine formulations were 
prepared by using the different ratios of the polymers 
such as the HPMC K15M, Guargum, Chitosan, Sodium 
bicarbonate was in cooperated as an effervescent 
substance to study the buoyancy of the dosage form due 
to liberation of co2, Sodiumalginate is used as viscous 
gel forming agent, Microcrystalcellulose used as binder, 
Talc is used as diluents, Magnesium stearate lubricant. 
The formulated  cefotaxime  tablet to be evaluated the 
following parameters as follow Weight variation, 
Hardness, Thickness, Friability, Drug content 
uniformity, Floating lag time, the in vitro cumulative 
amount of drug released was shown the F7 is 98% 
within 12 Hours the comparative studies with marketed 
formulations F7 show the better results. 
CONCLUSION: From the experimental results, it can 
be concluded that the sodium bicarbonate and sodium 
alginate has shown a predominant effect on the 
buoyancy lag time, while HPMC K15M and Guar gum 
have the predominant effect on drug release. Floating 
drug delivery of cefotaxime tablet has controlled release. 
In vitro release rate studies showed that the maximum 
drug release was observed F7 formulation upto 12 
hours. From the study it is evident that promising 
controlled release tablets of cefotaxime can be 
developed. Further detailed investigations are required 
to establish efficacy of these formulations. 
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